 Mesna
"Mesna" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE.
| Descriptor ID |
D015080
|
| MeSH Number(s) |
D02.455.326.146.100.050.490 D02.886.489.590 D02.886.645.600.055.050.500
|
| Concept/Terms |
Mesna- Mesna
- Sodium 2-Mercaptoethanesulphonate
- 2-Mercaptoethanesulphonate, Sodium
|
Below are MeSH descriptors whose meaning is more general than "Mesna".
Below are MeSH descriptors whose meaning is more specific than "Mesna".
This graph shows the total number of publications written about "Mesna" by people in this website by year, and whether "Mesna" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 | | 1998 | 0 | 1 | 1 | | 2001 | 0 | 1 | 1 | | 2021 | 1 | 0 | 1 | | 2024 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Mesna" by people in Profiles.
-
Nick HJ, Johnson CA, Stewart AR, Christeson SE, Bloomquist LA, Appel AS, Donkor AB, Veress LA, Logue BA, Bratcher PE, White CW. Mesna Improves Outcomes of Sulfur Mustard Inhalation Toxicity in an Acute Rat Model. J Pharmacol Exp Ther. 2024 01 17; 388(2):576-585.
-
Donkor AB, White CW, Nick HJ, Logue BA. Analysis of sodium 2-mercaptoethane sulfonate in rat plasma using high performance liquid chromatography tandem-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2022 Jan 15; 1189:123088.
-
Martin DD, Xu MQ, Evans TC. Characterization of a naturally occurring trans-splicing intein from Synechocystis sp. PCC6803. Biochemistry. 2001 Feb 06; 40(5):1393-402.
-
Elias AD, Wheeler C, Ayash LJ, Schwartz G, Ibrahim J, Mills L, McCauley M, Coleman N, Warren D, Schnipper L, Antman KH, Teicher BA, Frei E. Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support. Clin Cancer Res. 1998 Jun; 4(6):1443-9.
-
Demetri GD, Elias AD. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Hematol Oncol Clin North Am. 1995 Aug; 9(4):765-85.
-
Antman K, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, Elias A, Natale RB, Cooper RM, Barlogie B, Trump DL, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993 Jul; 11(7):1276-85.
-
Elias AD, Ayash LJ, Eder JP, Wheeler C, Deary J, Weissman L, Schryber S, Hunt M, Critchlow J, Schnipper L, et al. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support. J Clin Oncol. 1991 Feb; 9(2):320-7.
-
Eder JP, Elias AD, Ayash L, Wheeler CA, Shea TC, Schnipper LE, Frei E, Antman KH. A phase I trial of continuous-infusion cyclophosphamide in refractory cancer patients. Cancer Chemother Pharmacol. 1991; 29(1):61-5.
-
Antman KH, Elias A, Ryan L. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules. Semin Oncol. 1990 Apr; 17(2 Suppl 4):68-73.
-
Elias A, Ryan L, Aisner J, Antman KH. Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma. Semin Oncol. 1990 Apr; 17(2 Suppl 4):41-9.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|